Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
4-Phenyl-1,3-thiazole-2-amines as scaffolds for new antileishmanial agents.
Rodrigues CA
,
Dos Santos PF
,
da Costa MOL
,
Pavani TFA
,
Xander P
,
Geraldo MM
,
Mengarda A
,
de Moraes J
,
Rando DGG
.
???displayArticle.abstract???
Background: There is still a need for new alternatives in pharmacological therapy for neglected diseases, as the drugs available show high toxicity and parenteral administration. That is the case for the treatment of leishmaniasis, particularly to the cutaneous clinical form of the disease. In this study, we present the synthesis and biological screening of eight 4-phenyl-1,3-thiazol-2-amines assayed against Leishmania amazonensis. Herein we propose that these compounds are good starting points for the search of new antileishmanial drugs by demonstrating some of the structural aspects which could interfere with the observed activity, as well as suggesting potential macromolecular targets.
Methods: The compounds were easily synthesized by the methodology of Hantzsch and Weber, had their purities determined by Gas Chromatography-Mass spectrometry and assayed against the promastigote forms of Leishmania amazonensis as well as against two white cell lines (L929 and THP-1) and the monkey''s kidney Vero cells. PrestoBlue® and MTT viability assays were the methodologies applied to measure the antileishmanial and cytotoxic activities, respectively. A molecular modeling target fishing study was performed aiming to propose potential macromolecular targets which could explain the observed biological behavior.
Results: Four out of the eight compounds tested exhibited important anti-promastigote activity associated with good selectivity indexes when considering Vero cells. For the most promising compound, compound 6, IC50 against promastigotes was 20.78 while SI was 5.69. Compounds 3 (IC50: 46.63 μM; SI: 26.11) and 4 (IC50: 53.12 μM; SI: 4.80) also presented important biological behavior. A target fishing study suggested that S-methyl-5-thioadenosine phosphorylase is a potential target to these compounds, which could be explored to enhance activity and decrease the potential toxic side effects.
Conclusions: This study shows that 4-phenyl-1,3-thiazol-2-amines could be good scaffolds to the development of new antileishmanial agents. The S-methyl-5-thioadenosine phosphorylase could be one of the macromolecular targets involved in the action.
Fig. 1. Docking at the S-methyl-5-thioadenosine phosphorylase. (a) Co-crystallized ligand. (b) Compound 6 docked at the active site. Blue dashed lines: pi-stacking interactions; black dashed lines: hydrogen bonds (For color version, please access the online version of the article)
Altschul,
Basic local alignment search tool.
1990, Pubmed
Altschul,
Basic local alignment search tool.
1990,
Pubmed
Amnerkar,
Synthesis of some thiazolyl aminobenzothiazole derivatives as potential antibacterial, antifungal and anthelmintic agents.
2011,
Pubmed
Appleby,
The structure of human 5'-deoxy-5'-methylthioadenosine phosphorylase at 1.7 A resolution provides insights into substrate binding and catalysis.
1999,
Pubmed
Bilbao-Ramos,
Nuclease activity and ultrastructural effects of new sulfonamides with anti-leishmanial and trypanocidal activities.
2012,
Pubmed
Carrera,
Assignment of the gene for methylthioadenosine phosphorylase to human chromosome 9 by mouse-human somatic cell hybridization.
1984,
Pubmed
Croft,
Public-private partnership: from there to here.
2005,
Pubmed
Della Ragione,
Deficiency of 5'-deoxy-5'-methylthioadenosine phosphorylase activity in malignancy. Absence of the protein in human enzyme-deficient cell lines.
1992,
Pubmed
Della Ragione,
5'-Deoxy-5'-methylthioadenosine phosphorylase and p16INK4 deficiency in multiple tumor cell lines.
1995,
Pubmed
Ghaemmaghami,
Discovery of 2-aminothiazoles as potent antiprion compounds.
2010,
Pubmed
Gorczynski,
Synthesis and evaluation of substituted 4-aryloxy- and 4-arylsulfanyl-phenyl-2-aminothiazoles as inhibitors of human breast cancer cell proliferation.
2004,
Pubmed
Jones,
Development and validation of a genetic algorithm for flexible docking.
1997,
Pubmed
Kaiser,
Repurposing of the Open Access Malaria Box for Kinetoplastid Diseases Identifies Novel Active Scaffolds against Trypanosomatids.
2015,
Pubmed
Kamatani,
Selective killing of human malignant cell lines deficient in methylthioadenosine phosphorylase, a purine metabolic enzyme.
1981,
Pubmed
Lall,
Viability Reagent, PrestoBlue, in Comparison with Other Available Reagents, Utilized in Cytotoxicity and Antimicrobial Assays.
2013,
Pubmed
Liu,
PharmMapper server: a web server for potential drug target identification using pharmacophore mapping approach.
2010,
Pubmed
Papadopoulou,
Antitrypanosomal activity of 5-nitro-2-aminothiazole-based compounds.
2016,
Pubmed
Rando,
Antileishmanial activity screening of 5-nitro-2-heterocyclic benzylidene hydrazides.
2008,
Pubmed
Soong,
Immunopathogenesis of non-healing American cutaneous leishmaniasis and progressive visceral leishmaniasis.
2012,
Pubmed
Williams-Ashman,
Trends in the biochemical pharmacology of 5'-deoxy-5'-methylthioadenosine.
1982,
Pubmed
Yap,
PaDEL-descriptor: an open source software to calculate molecular descriptors and fingerprints.
2011,
Pubmed
de Brito,
Cyclohexene-fused 1,3-oxazines with selective antibacterial and antiparasitic action and low cytotoxic effects.
2017,
Pubmed
de Moraes,
Antischistosomal Activity of Oxindolimine-Metal Complexes.
2015,
Pubmed